ArticleJournal of thoracic disease2025
Immune-related cardiotoxicities predict immune checkpoint inhibitors treatment for advanced non-small cell lung cancer: a retrospective multi-center study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitor (ICI) therapy is a cornerstone in the treatment of advanced non-small cell lung cancer (NSCLC), but immune-related cardiotoxicities remain a concern. Whether immune-related cardiotoxicities serve as independent prognostic predictors for NSCLC remains debated. This study aimed to investigate the prognostic value of immune-related cardiotoxicities and develop a predictive model for survival outcomes in NSCLC patients receiving ICI therapy. Methods: This retrospective multi-center study included NSCLC patients from nine centers who received at least one ICI cycle from 2019 to 2024. Demographic and clinical indicators were analyzed for associations with overall survival (OS). A prognostic model based on Cox regression and a nomogram was developed and validated. Results: Of 187 patients, the 1-, 3-, and 5-year survival rates of all participants was 0.903 [95% confidence interval (CI) 0.857-0.951], 0.759 (95% CI: 0.666-0.865) and 0.528 (95% CI: 0.361-0.773) respectively and 80 (42.8%) experienced immune-related cardiotoxicities. Kaplan-Meier survival analyses revealed that immune-related cardiotoxicities and immune-related adverse events (irAEs) were not associated with OS (P=0.10; P=0.20). Multivariate Cox regression analyses on OS showed an independent predictive value of platelet-to-lymphocyte ratio (PLR) [hazard ratio (HR) 1.002, 95% CI: 1.000-1.004, P=0.02], carcinoembryonic antigen (CEA) (HR 1.005, 95% CI: 1.002-1.007, P<0.001) and cytokeratin-19 fragment 21-1 (CYFRA21-1) (HR 1.004, 95% CI: 1.001-1.008, P=0.02) for OS in advanced NSCLC patients. A nomogram was constructed and the area under the curve (AUC) was 0.757, 0.741, and 0.815 at 1-, 3-, and 5-year. A prognostic model incorporating PLR, CEA and CYFRA21-1 resulted in an optimal performance to predict the prognosis. Additionally, smoking was associated with the occurrence of immune-related cardiotoxicities. Conclusions: Mild irAEs or immune-related cardiotoxicities (grade 1-2) did not extend median OS in NSCLC patients. The prognostic model incorporating PLR, CEA, and CYFRA21-1 could contribute to predicting the treatment efficacy and prognosis of ICI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.